✦ LIBER ✦

Immunosuppressant supplementation to infliximab in Crohn's disease with extraintestinal involvement: A benefit in the long term?

✍ Scribed by Mariabeatrice Principi; Enzo Ierardi; Daniela Antonicelli; Alberto Pastorelli; Antonio Pisani; Alfredo Di Leo; Carmine Panella; Antonio Francavilla

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 56 KB
Volume: 14
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.20460

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer in Crohn's Disease patients treat

Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study

✍ Livia Biancone; Carmelina Petruzziello; Ambrogio Orlando; Anna Kohn; Sandro Ardi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 2 views

## Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multic

Pure ileal Crohn's disease without colon

Pure ileal Crohn's disease without colonic involvement after a long ileo-colonic anastomosis (Lester Martin Procedure) for Hirschsprung's disease: An argument favoring a specific sensitivity of the ileum in a subset of patients with Crohn's disease

✍ Xavier Dray; Harry Sokol; Kouroche Vahedi; Anne Lavergne-Slove; Philippe Marteau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Lack of clinical long-term benefit with

Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts

✍ Giuseppe Gioia; Alberto Benassi; Raghar Mohendra; Khaza Chowdhury; Iqbal Masood; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 3 views

## Abstract Background: Small randomized trials have shown short‐term improved outcome with drug‐eluting stents (DES) over bare metal stent (BMS) in saphenous vein graft (SVG) interventions by reducing in‐stent restenosis and target vessel revascularization (TVR). It is not clear, however, if these